miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial

被引：0
|
作者：
Mathe, Y. Gaston [1 ]
Martin-Lanneree, S. [2 ]
Vazart, C. [2 ]
Fontaine, K. [2 ]
Mulot, C. [3 ]
Caumont, A. [4 ]
Montestruc, F. [4 ]
Le Malicot, K. [5 ]
Lepage, C. [6 ]
Taieb, J. [7 ]
Laurent-Puig, P. [8 ]
机构：
[1] IntegraGen SA, Mol Diagnost, Evry, France
[2] IntegraGen, R&D, Evry, France
[3] INSERM, U1147, Paris, France
[4] Biostat EXYSTAT, Malakoff, France
[5] FFCD, Biostat, Dijon, France
[6] CHU Dijon, Clin Oncol, Dijon, France
[7] Hop European George Pompidou, Dept Gastroenterol & Digest Oncol, Paris, France
[8] Paris Descartes Univ, UMR1147, Paris, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
521P
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [41] Postoperative intra-abdominal infection is an independent prognostic factor of disease-free survival and disease-specific survival in patients with stage II colon cancer
    P. Sánchez-Velázquez
    M. Pera
    M. Jiménez-Toscano
    X. Mayol
    X. Rogés
    L. Lorente
    M. Iglesias
    M. Gallén
    Clinical and Translational Oncology, 2018, 20 : 1321 - 1328
  • [42] Postoperative intra-abdominal infection is an independent prognostic factor of disease-free survival and disease-specific survival in patients with stage II colon cancer
    Sanchez-Velazquez, P.
    Pera, M.
    Jimenez-Toscano, M.
    Mayol, X.
    Roges, X.
    Lorente, L.
    Iglesias, M.
    Gallen, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (10): : 1321 - 1328
  • [43] Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
    Roth, Arnaud D.
    Tejpar, Sabine
    Delorenzi, Mauro
    Yan, Pu
    Fiocca, Roberto
    Klingbiel, Dirk
    Dietrich, Daniel
    Biesmans, Bart
    Bodoky, Gyoergy
    Barone, Carlo
    Aranda, Enrique
    Nordlinger, Bernard
    Cisar, Laura
    Labianca, Roberto
    Cunningham, David
    Van Cutsem, Eric
    Bosman, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 466 - 474
  • [44] Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.
    Zaanan, Aziz
    Shi, Qian
    Taieb, Julien
    Alberts, Steven R.
    Meyers, Jeffrey P.
    Smyrk, Thomas C.
    Julie, Catherine
    Zawadi, Ayman
    Tabernero, Josep
    Mini, Enrico
    Goldberg, Richard M.
    Folprecht, Gunnar
    Van Laethem, Jean Luc
    Le Malicot, Karine
    Sargent, Daniel J.
    Laurent-Puig, Pierre
    Sinicrope, Frank A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Isolated Tumor Cells are a Negative Prognostic Factor for Disease-free and Overall Survival in Stage I & II Colon Cancer Patients: A Propensity Score Analysis
    Weixler, B.
    Warschkow, R.
    Gueller, U.
    Zettl, A.
    Schmied, B. M.
    Viehl, C. T.
    Von Holzen, U.
    Zuber, M.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S12 - S12
  • [46] Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data.
    Ajani, Jaffer A.
    Leung, Lisa
    Kanters, Steve
    Singh, Prianka
    Kurt, Murat
    Kim, Inkyu
    Pourrahmat, Mir-Masoud
    Friedman, Howard S.
    Navaratnam, Prakash
    Reardon, Gregory
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 321 - 321
  • [47] Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial
    Chibaudel, Benoist
    Henriques, Julie
    Rakez, Manel
    Brenner, Baruch
    Kim, Tae Won
    Martinez-Villacampa, Mercedes
    Gallego-Plazas, Javier
    Cervantes, Andres
    Shim, Katharine
    Jonker, Derek
    Guerin-Meyer, Veronique
    Mineur, Laurent
    Banzi, Chiara
    Dewdney, Alice
    Dejthevaporn, Thitiya
    Bloemendal, Haiko J.
    Roth, Arnaud
    Moehler, Markus
    Aranda, Enrique
    Van Cutsem, Eric
    Tabernero, Josep
    Schmoll, Hans-Joachim
    Hoff, Paulo M.
    Andre, Thierry
    de Gramont, Aimery
    JAMA NETWORK OPEN, 2020, 3 (10) : E2020425
  • [48] Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy
    Ahn, Joong Bae
    Kim, Se Hyun
    Shin, Sang Joon
    Lee, Kang Young
    Kim, Tae Il
    Hur, Hyuk
    Min, Byung Soh
    Kim, Nam Kyu
    Chung, Hyun Cheol
    Roh, Jae Kyung
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for state III colon cancer (NO16968): Impact of age on disease-free survival (DFS)
    Haller, D. G.
    Cassidy, J.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F. G.
    Price, T. J.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] CAPOX Associated With Toxicities of Higher Grade but Improved Disease-Free Survival When Compared With FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
    Loree, Jonathan M.
    Mulder, Karen E.
    Ghosh, Sunita
    Spratlin, Jennifer L.
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 172 - 177
12345